What low‑molecular‑weight heparin regimen should be used for venous thrombo‑embolism prophylaxis in an adult with severe sepsis?

LMWH Regimen for VTE Prophylaxis in Severe Sepsis

Administer daily subcutaneous low-molecular-weight heparin (LMWH) as the preferred agent for VTE prophylaxis in adults with severe sepsis, with specific dosing adjustments based on renal function. 1

Dosing Algorithm

For Normal Renal Function (CrCl ≥ 30 mL/min)

• Use standard prophylactic LMWH once daily (e.g., enoxaparin 40 mg subcutaneously daily or equivalent) 1
• This is superior to unfractionated heparin (UFH) given twice or three times daily 1

For Renal Impairment (CrCl < 30 mL/min)

• Use dalteparin (Grade 1A recommendation) 1
• Alternative: Select another LMWH with low degree of renal metabolism 1
• Alternative: Switch to UFH if LMWH contraindicated in this setting 1

Why LMWH Over UFH

The Surviving Sepsis Campaign guidelines provide a strong recommendation (moderate quality evidence) for LMWH rather than UFH for VTE prophylaxis 1. This preference is based on:

• More predictable anticoagulation with once-daily dosing
• Superior efficacy demonstrated in reducing VTE events 2
• Lower rates of bleeding complications compared to UFH 3
• Reduced 28-day mortality in septic patients 2
• Decreased inflammatory markers and multiple organ dysfunction syndrome 2

Recent data from critically ill patients confirms LMWH's favorable safety profile, showing lower rates of life-threatening hemorrhage and fewer transfusion requirements compared to UFH 4.

Combination Therapy

Add mechanical prophylaxis (intermittent pneumatic compression devices) whenever possible 1. This combination approach provides additional protection without increasing bleeding risk, though the recommendation strength is weak due to lower quality evidence.

Contraindications Requiring Mechanical-Only Prophylaxis

Switch to mechanical prophylaxis alone (graduated compression stockings or intermittent compression devices) when pharmacologic prophylaxis is contraindicated 1:

• Thrombocytopenia (particularly platelets < 30,000-50,000/µL)
• Severe coagulopathy
• Active bleeding
• Recent intracerebral hemorrhage

Resume pharmacologic prophylaxis as soon as the contraindication resolves 1.

Critical Pitfalls to Avoid

1. Don't use UFH twice daily - there is no evidence supporting UFH twice daily as equivalent to LMWH once daily or UFH three times daily 5

2. Don't forget renal dosing - standard LMWH doses in severe renal impairment increase bleeding risk; dalteparin has the strongest evidence for safety in this population 1

3. Don't withhold prophylaxis in moderate thrombocytopenia - emerging evidence suggests prophylactic anticoagulation may be considered even with platelets 30,000-50,000/µL in selected patients, though this remains an area requiring clinical judgment 6

4. Don't assume all LMWHs are equivalent in renal failure - dalteparin specifically has Grade 1A evidence for use when CrCl < 30 mL/min due to its non-renal clearance mechanisms 1, 7

Clinical Benefits Beyond VTE Prevention

Meta-analysis data demonstrates that LMWH in septic patients provides additional benefits beyond thromboprophylaxis 2:

• Improved coagulation parameters (reduced PT, increased platelet count)
• Decreased inflammatory cytokines (TNF-α, IL-6)
• Lower D-dimer levels
• Reduced APACHE II scores
• Decreased 28-day mortality (RR 0.52)

These pleiotropic effects support aggressive VTE prophylaxis in this high-risk population.